GlassScriptPhysician profile
Joseph Dewane
NPI 1578593133
$941.88
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $179 · 2021: $178 · 2022: $224 · 2023: $57.96 · 2024: $54.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $112.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $335.51 | 2019-2023 | Lo Loestrin Fe |
| Pfizer INC. | $236.46 | 2019-2024 | |
| Channel Medsystems, INC. | $77.41 | 2022 | |
| Aspira Women'S Health INC | $62.71 | 2021 | |
| Roche Diagnostics Corporation | $35.17 | 2019-2020 | |
| Agile Therapeutics, INC. | $31.10 | 2022-2024 | Twirla |
| Lupin INC. | $30.53 | 2020 | |
| Angiodynamics, INC. | $22.64 | 2020 | |
| Convatec INC. | $20.73 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.07 | 2019 | |
| Organon LLC | $17.67 | 2024 | |
| Avion Pharmaceuticals | $16.21 | 2022 | |
| Glaxosmithkline, LLC. | $13.52 | 2021 | |
| Allergan, INC. | $11.14 | 2020 | |
| Exeltis, USA INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Dewane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.